Neuronal seipin knockout facilitates Aβ-induced neuroinflammation and neurotoxicity via reduction of PPARγ in hippocampus of mouse by Yun Qian et al.
RESEARCH Open Access
Neuronal seipin knockout facilitates
Aβ-induced neuroinflammation and
neurotoxicity via reduction of PPARγ
in hippocampus of mouse
Yun Qian1,3†, Jun Yin2†, Juan Hong1,2, Guoxi Li1,2, Baofeng Zhang2, George Liu4, Qi Wan3* and Ling Chen1,2*
Abstract
Background: A characteristic phenotype of congenital generalized lipodystrophy 2 (CGL2) that is caused by
loss-of-function of seipin gene is mental retardation. Seipin is highly expressed in hippocampal pyramidal cells
and astrocytes. Neuronal knockout of seipin in mice (seipin-KO mice) reduces the hippocampal peroxisome
proliferator-activated receptor gamma (PPARγ) level without the loss of pyramidal cells. The down-regulation of
PPARγ has gained increasing attention in neuroinflammation of Alzheimer’s disease (AD). Thus, the present study
focused on exploring the influence of seipin depletion on β-amyloid (Aβ)-induced neuroinflammation and Aβ
neurotoxicity.
Methods: Adult male seipin-KO mice were treated with a single intracerebroventricular (i.c.v.) injection of Aβ25–35
(1.2 nmol/mouse) or Aβ1–42 (0.1 nmol/mouse), generally a non-neurotoxic dose in wild-type (WT) mice. Spatial
cognitive behaviors were assessed by Morris water maze and Y-maze tests, and hippocampal CA1 pyramidal cells
and inflammatory responses were examined.
Results: The Aβ25–35/1–42 injection in the seipin-KO mice caused approximately 30–35 % death of pyramidal cells
and production of Hoechst-positive cells with the impairment of spatial memory. In comparison with the WT mice,
the number of astrocytes and microglia in the seipin-KO mice had no significant difference, whereas the levels of
IL-6 and TNF-α were slightly increased. Similarly, the Aβ25–35/1–42 injection in the seipin-KO mice rather than the WT
mice could stimulate the activation of astrocytes or microglia and further elevated the levels of IL-6 and TNF-α.
Treatment of the seipin-KO mice with the PPARγ agonist rosiglitazone (rosi) could prevent Aβ25–35/1–42-induced
neuroinflammation and neurotoxicity, which was blocked by the PPARγ antagonist GW9962. In the seipin-KO mice,
the level of glycogen synthase kinase-3β (GSK3β) phosphorylation at Tyr216 was elevated, while at Ser9, it was
reduced compared to the WT mice, which were corrected by the rosi treatment but were unaffected by the
Aβ25–35 injection.
Conclusions: Seipin deficiency in astrocytes increases GSK3β activity and levels of IL-6 and TNF-α through reducing
PPARγ, which can facilitate Aβ25–35/1–42-induced neuroinflammation to cause the death of neuronal cells and
cognitive deficits.
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Background
Congenital generalized lipodystrophy (CGL) is an auto-
somal recessive disorder that is characterized by a near-
total loss of adipose tissue [1]. Genome-wide linkage
analysis has identified two loci related to CGL, i.e., CGL1
mutations in the 1-acylglycerol-3-phosphate O-acyl trans-
ferase 2 (AGPAT2) gene and CGL2 mutations in the
Berardinelli-Seip congenital lipodystrophy 2 (BSCL2) gene
that encodes seipin [2]. CGL2 patients with loss-of-
function mutations in the seipin gene exhibit much higher
rates of mental retardation than CGL1 patients [3, 4].
Seipin is highly expressed in the neuronal cells of the cor-
tex, cerebellum, hippocampus, and hypothalamus [5, 6].
The seipin knockout in rats or mice causes spatial cogni-
tive deficits through the synaptic dysfunction in hippo-
campal CA1 regions without loss of pyramidal cells [5, 7].
Seipin, an exclusive endoplasmic reticulum-residing
N-glycosylated protein, can affect the generation of per-
oxisome proliferator-activated receptor gamma (PPARγ)
[8]. The level of PPARγ is reduced in the embryonic
fibroblasts of seipin-deficient mice [9]. We have recently
reported that the neuronal knockout of seipin in mice
(seipin-KO mice) reduces the expression of the hippo-
campal PPARγ [7, 10, 11]. The PPARγ is expressed in
astrocytes and microglia and exerts an anti-inflammatory
effect [12]. PPARγ agonists can inhibit the activations of
microglia and astrocytes [13] and reduce the production
of pro-inflammatory cytokines [14]. PPARγ deficiency has
been reported to increase the neuroinflammation in aller-
gic encephalomyelitis [15] and multiple sclerosis [16]. The
levels of pro-inflammatory cytokines, such as tumor ne-
crosis factor-α (TNF-α), interleukin-6 (IL-6), are elevated
in Alzheimer’s disease (AD) brains [17]. The activation of
PPARγ can enhance the cognitive reserve in humans with
AD and in mouse model for AD amyloidosis [18]. The
activation of PPARγ can improve hippocampus-dependent
cognitive deficits in AD mouse models [19]. The PPARγ
activation has been recently shown to mitigate the neuronal
inflammation in chronic and acute neurological insults
[20]. The PPARγ has received increasing attention in AD
due to its anti-inflammatory function [21]. The hippocam-
pal astrocytes express the seipin protein [10]. Thus, it
should be interesting to examine whether seipin deficiency
in astrocytes through reducing PPARγ affects Aβ-induced
neuroinflammation and neurotoxicity.
The beneficial effects of PPARγ ligands potentially
involve the suppression of signal transducer and activa-
tor of transcription (STAT) [22]. Li et al. have reported
the elevation of STAT3 activity in the hippocampus of
seipin-KO mice [10]. The STAT family of transcription
factors has a central role in inflammatory reactions
through regulating the expressions of multiple cytokines.
In addition, the activation of STAT3 is known to be
crucial for the differentiation of astrocytes [23]. Adult
seipin-KO mice showed an increase in the astrocytic
differentiation of progenitor cells in the hippocampal
dentate gyrus, which can be corrected by the activation
of PPARγ [10]. The STAT3 activation is highly dependent
on the phosphorylation of glycogen synthase kinase-3
(GSK3) [24]. GSK3 is a constitutively active Ser/Thr kin-
ase consisting of GSK3α and GSK3β isoforms. GSK3β has
been identified as a strong promoter of pro-inflammatory
cytokines, including TNF-α and IL-6 [25, 26].
Among the Aβ fragments, a peptide bearing 11 amino
acids (25–35) (Aβ25–35) is the shortest fragment of Aβ
that is processed in vivo by brain proteases [27]. This
peptide retains the ability to self-aggregate and elicits
essentially the same toxicity as the full-length peptide
despite lacking the hydrophobic C terminal sequence of
five amino acids that is present in Aβ1–40 [28]. In this
study, we treated the adult male seipin-KO mice with a
single i.c.v. injection of Aβ25–35 at a non-neurotoxic dose
in control mice [29, 30], and then observed the Aβ25–35
neurotoxicity (the death of the hippocampal pyramidal
cells) and Aβ25–35-induced neuroinflammation (the
activation of astrocytes and microglia, the levels of IL-6
and TNF-α). To test the involvement of reduced PPARγ
by seipin deficiency, we investigated the effects of the
PPARγ agonist and the PPARγ antagonist on Aβ25–35-in-
duced neuroinflammation and Aβ25–35 neurotoxicity in
the seipin-KO mice. The results of the present study
indicate that seipin deficiency in astrocytes facilitates the
Aβ25–35-induced neuroinflammation through reducing
PPARγ to elevate GSK3β activity, which causes the death
of pyramidal cells leading to the spatial cognitive deficits.
Methods
Generation of seipin knockout (seipin-KO) mice
All animal handling procedures followed the guidelines
for Laboratory Animal Research of Nanjing Medical
University. The use of animals was approved by the
Institutional Animal Care and Use Committee of Nanjing
Medical University. The mice were maintained in constant
environmental conditions (temperature 23 ± 2 °C, humid-
ity 55 ± 5 %, and a 12:12-h light/dark cycle). The neuronal
seipin-KO mice were generated as described elsewhere
[11]. The genotypes of the seipin-KO mice were identified
by PCR using genomic DNA from their tails. The DNA
was amplified with the following primers: 5′-CTTGTC
TCAAAGGGGTCT-3′ (forward primer for loxP) and 5′-
TCAACAGAACAGACGCT-3′ (reverse primer for loxP);
and 5′-GCGGTCTGGCAGTAAAAACTATC-3′ (forward
primer for nestin-Cre) and 5′-GTGAAACAGCATTG
CTGTCACTT-3′ (reverse primer for nestin-Cre). All
animals received a standard laboratory diet before and
after all procedures. In this study, 16-week-old male
seipin-KO mice (n = 88) and wild-type (WT) mice (n = 56)
were used at the beginning of all experiments. All mice
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were randomly assigned to one of the following six experi-
mental groups: WT mice (n = 24), Aβ25–35-treated WT
mice (Aβ25–35-mice, n = 16), Aβ1–42-treated WT mice
(Aβ1–42-mice, n = 16), seipin-KO mice (n = 32), Aβ25–35-
treated seipin-KO mice (Aβ25–35-KO mice, n = 40), and
Aβ1–42-treated seipin-KO mice (Aβ1–42-KO mice, n = 16).
Each experiment was performed by two experimenters
who were blinded to the experimental groups. The behav-
ioral tests (n = 16 mice for each group) and histological
observations (n = 8 mice for each group) or Western blot
analyses (n = 8 mice for each group) were sequentially
performed in the same cohorts.
Injection (i.c.v.) of Aβ25–35 and Aβ1–42
The Aβ25–35 (Sigma, St. Louis, MO, USA) was aggre-
gated by incubation in distilled water (1 mg/ml) at 37 °C
for 4 days and diluted to the final concentration with
saline immediately before the experiment [30]. After this
treatment, two types of birefringent fibril-like structures
and globular aggregates of Aβ25–35 can be observed by
light microscopic observation [30]. The Aβ1–42 (Sigma,
St. Louis, MO, USA) was dissolved in 1,1,1,3,3,3-hexa-
fluoro-2-propanol (HFIP, Sigma-Aldrich) and then flash-
freezed in liquid nitrogen and lyophilized to completely
remove the solvent [31]. Lyophilized Aβ1–42 was dissolved
in 100 mM NaOH at a concentration of 6 mg/ml, aliquoted
in 50 μl volumes [32]. The mice were anesthetized with
ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.)
[33] and placed in a stereotactic apparatus (Motorized
Stereotaxic StereoDrive; Neurostar). The “aggregated”
Aβ25–35 (1.2 nmol/mouse at 2 μl) or the Aβ1–42 (0.1 nmol/
2 μl in 0.1 M phosphate-buffered saline) was injected into
the ventricles (0.3 mm posterior, 1.0 mm lateral, and
2.5 mm ventral to the bregma) using a stepper-motorized
micro-syringe at a rate of 0.3 μl/min [34]. The injection site
was confirmed by the injection of Indian ink in the prelim-
inary experiments. The mice infused with the same volume
of vehicle served as the control group.
Drug administration
The PPARγ agonist rosiglitazone (rosi; Enzo, Farmingdale,
NY) and the PPARγ antagonist GW9962 (Sigma, St. Louis,
MO, USA) were dissolved in dimethyl sulfoxide (DMSO)
and then diluted in 0.9 % saline to a final concentration of
0.5 % DMSO. The oral administration (p.o.) of rosi was
given daily at a dose of 5 mg/kg [7]. The GW9962 (1 mg/
kg/day) was injected intraperitoneally (i.p.) [35].
Behavioral examination
The behavioral performances on days 5–14 after Aβ25–35
injection were captured via video recording (Winfast
PVR; Leadtek Research, Fremont, CA) and analyzed
using TopScan Lite 2.0 (Clever Sys., Reston, VA). Morris
water maze task: The water maze task was consecutively
performed to examine the spatial memory [29]. A pool
(diameter = 120 cm) made of black-colored plastic was
prepared. The water temperature was maintained at 20
± 1 °C with a bath heater that was used before the
sessions. On days 1–2 of training, a cylindrical black-
colored platform (diameter = 7 cm) was placed 0.5 cm
above the surface of the water. A mouse was randomly
released into one of the four different quadrants and
allowed to swim for 90 s. The latency to reach the visible
platform was measured. On days 3–7 of the training, the
platform was moved to the opposite quadrant of the
previously visible platform and submerged 1 cm below
the surface of the water. Four trials were conducted each
day with an intertrial interval of 30 min. The average
swimming speeds (m/s) and latencies (s) to reach the
platform were scored for all trials. If the mouse was
unable to reach the platform within 90 s, the experi-
menters gently assisted it onto the platform and allowed
it to remain there for 15 s. Each mouse began in one of
the four quadrants, which was selected in a random
manner. On day 8 of the training, a probe trial was
performed by removing the platform. The mouse was
released from the opposite quadrant relative to the
previous location of the platform and allowed to swim
for 90 s. The percentages of swimming time spent in the
target quadrant, opposite quadrant, and right and left
adjacent quadrants were determined. Y-maze task:
Spatial working memory performance was assessed by
recording spontaneous alternation behavior in a Y-maze
[30]. A Y-maze task was performed 48 h after the probe
trial task. The Y-maze was constructed of black-painted
wood. Each arm was 40-cm long, 13-cm high, 3-cm wide
at the bottom, and 10-cm wide at the top, and the arms
converged at equal angles. Each mouse was placed at the
end of one arm and allowed to move freely through the
maze during an 8-min session. The series of arm entries
were recorded visually, and arm entries were considered
to be completed when the hind paws of the mouse were
completely placed in the arm. Alternations were defined
as successive entries into the three arms on overlapping
triplet sets. The percentage of alternations was calcu-
lated as the ratio of actual to possible alternations
(defined as the total number of arm entries minus two).
The scorers were blinded to the treatment groups.
Histological examination
The mice were anesthetized with chloral hydrate
(400 mg/kg, i.p.) and perfused with 4 % paraformalde-
hyde. The brains were removed and immersed in 4 %
paraformaldehyde at 4 °C overnight.
Toluidine blue staining: The brains were processed for
paraffin embedding, and coronal sections (5 μm) were
cut. The pyramidal cells in the hippocampal CA1 region
were identified using a conventional light microscope
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(Olympus DP70, Tokyo, Japan) with a 60× objective.
The healthy pyramidal neurons exhibited round cell
bodies with plainly stained nuclei. Stereological counting
CA1 pyramidal cells: The brains were transferred into
30 % sucrose. After gradient dehydration, the coronal
sections of the hippocampus (40 μm) were cut with a
freezing microtome (Leica, Nussloch, Germany) and
stained with toluidine blue. Every fourth section was
obtained for consecutive cell quantification analyses.
Stereological cell counting was performed by a stereologi-
cal system, consisting of a light microscope with a CCD
camera (Olympus DP70), a motorized specimen stage for
automatic sampling (MicroBrightField, Williston, USA),
and a computer running Microbrightfield Stereo Investi-
gator software (Microbrightfield, Williston, VT, USA) [36].
All counts were performed by the same investigator, who
was blind to the treatment. The total numbers of healthy
pyramidal cells throughout the hippocampal CA1 region
were counted using the optical fractionators’ method. The
section thickness was measured using a dissector height of
10 μm. The layer of pyramidal cells was defined according
to the terminology of Blackstad [37]. The boundary
between the CA3 and CA1 subregions was identified by
the differential thickness of the cell layers and by the
smaller cell somas of the CA1 subregion. The boundary
between CA1 and the subiculum was defined as the line
separating the contiguous cells of CA1 from the more
widely spaced cells of the subiculum.
Hoechst staining: Coronal paraffin sections (5 μm) were
incubated in Hoechst 33342 (1 μg/ml, Cell Signaling
Technology, Inc., Boston, MA, USA) for 2 min. Quantita-
tive analyses of Hoechst-positive cells: Hoechst-positive
(Hoechst+) cells in hippocampal CA1 region were observed
by a conventional light microscope (Olympus DP70, Japan)
with 60× objective and counted. The density of Hoechst+
cells was expressed as the number of cells per millimeter
length along the pyramidal cells layer.
GFAP and Iba1 staining: The hippocampal sections
(40 μm) were cut using a cryostat. Every fourth section
was obtained with a randomly chosen starting section.
The free-floating sections were blocked with 3 % normal
goat serum for 60 min. Glial fibrillary acidic protein
(GFAP) and ionized calcium-binding adapter molecule 1
(Iba1) immuno-staining were performed using the
following primary antibodies and incubation at 4 °C
overnight: mouse anti-GFAP antibody (1:500; Millipore,
Billerican, MA, USA) and goat polyclonal anti-Iba1
antibody (1:500; Abcam, Cambridge, UK). Then, the
sections were incubated in biotin-labeled goat anti-
mouse IgG antibody (1:400; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) or biotin-labeled rabbit anti-goat
IgG antibody (1:500; Bioworld Technology, Inc., St.
Louis Park, MN, USA) for 2 h at room temperature.
Immuno-reactivity was visualized based on the avidin-
biotin-horseradish peroxidase complex (ABC Elite; Vector
Laboratories, Inc., Burlingame, CA, USA).
Counting GFAP- and Iba1-positive cells in the hippo-
campal CA1: The GFAP-positive (GFAP+) cells and Iba1-
positive (Iba1+) cells in the hippocampal CA1 radiatum
layer were counted using a conventional light microscope
(Olympus DP70). The radiatum layer was outlined at ×5
magnification. Systematic random sampling was achieved
with a uniform sampling grid superimposed randomly
over the region. A counting frame was placed in each
square of the grid, and the cells were counted within that
frame at ×40 magnification. A cell was counted if the
nucleus was stained and was (a) in focus, (b) within the
counting frame or crossed the green counting frame
inclusion line, and (c) within the optical disector. Total
estimated cell number per section = number of counted
cells × (1/ssf) × (1/asf) × (1/hsf), where ssf is the section
sampling fraction, asf is the area sampling fraction, and
hsf is the height sampling fraction [38]. The densities of
GFAP+ cells and Iba1+ cells are expressed as the mean
numbers per mm3, which were normalized to the control
value obtained from WT mice [39].
Seipin/GFAP or Iba1 double immuno-staining: The
coronal sections (5 μm in thickness) were placed in
gelatine-coated slides, blocked with 3 % normal goat serum,
and then incubated in rabbit anti-seipin antibody (1:200;
Abcam) at 4 °C overnight, which was revealed using CY3-
labeled anti-rabbit IgG antibody (1:200; Millipore) or FITC-
labeled anti-rabbit antibody (1:200; Millipore) and mouse
monoclonal anti-GFAP antibody (1:200; Millipore) or goat
polyclonal anti-Iba1 antibody (1:500; Abcam), which was
revealed using FITC-labeled anti-mouse antibody (1:50;
Millipore) or CY3-labeled anti-goat IgG antibody (1:200;
Millipore). The immune-positive cells/fibers were observed
by a confocal laser-scanning microscope (Leica, Heidelberg,
Germany).
Western blot analyses
The mice were decapitated under deep anesthesia with
chloral hydrate. The hippocampus was quickly removed
and homogenized in a lysis buffer containing 50 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 10 mM
NaF, 1 mM sodium orthovanadate, 1 % Triton X-100,
0.5 % sodium deoxycholate, 1 mM phenyl-methylsulfonyl
fluoride, and a protease inhibitor cocktail (Complete;
Roche, Mannheim, Germany). The protein concentration
was determined with a BCA Protein Assay Kit (Pierce
Biotechnology, Rockford, IL, USA). The total proteins
(20 μg) were separated by SDS-poly-acrylamide gel
electrophoresis (SDS-PAGE) and transferred to a polyvi-
nylidene difluoride membrane. The membranes were
incubated with 5 % nonfat dried milk in Tris-buffered
saline containing 0.1 % Tween 20 for 60 min at room
temperature and were then incubated with a mouse
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monoclonal anti-phospho-GSK3β (Tyr216) antibody
(1:1000; Cell Signaling Technology), a rabbit monoclonal
anti-phospho-GSK3β (Ser9) antibody, and an anti-
phospho-STAT3 antibody (1:1000; Cell Signaling Technol-
ogy); a rabbit polyclonal anti-IL-6 antibody (1:1000;
Abcam), a mouse monoclonal anti-TNF-α antibody and a
PPARγ antibody (1:200; Santa Cruz Biotechnology); or a
mouse monoclonal anti-β-actin antibody (1:1000; Cell Sig-
naling Technology) and a rabbit monoclonal anti-GAPDH
antibody (1:1000; Cell Signaling Technology) at 4 °C over-
night. The membranes were then incubated with HRP-
labeled secondary antibodies (1:10,000; Millipore). The
blots were stripped by incubation in a stripping buffer
(Restore, Pierce) for 5 min, incubated with rabbit poly-
clonal antibodies for GSK3β or STAT3 (1:1000; Cell Sig-
naling Technology) and developed using an ECL
Detection Kit (Millipore). The Western blot bands were
scanned and analyzed with an image analysis software
package (ImageJ; NIH Image, Bethesda, MD, USA).
Data analysis/statistics
The data were retrieved and processed with the Microcal
Origin 8.0 software. The group data are expressed as the
means ± standard errors, and significance was tested
with Student’s t tests or ANOVAs with or without re-
peated measures, followed by Bonferroni post hoc ana-
lysis for multiple comparisons. The results of the Morris
water maze test were analyzed using repeated-measures
ANOVA. The statistical analyses were performed using
Stata 7 software (STATA Corporation, College Station,
TX, USA). Differences were considered statistically sig-
nificant at P < 0.05.
Results
Seipin deficiency enhances Aβ25–35-induced cognitive
deficits
Spatial memory was examined using place learning in a
Morris water maze task from day 5 after the injection
(i.c.v.) of Aβ25–35. The mean latency required to find the
visible platform on days 1–2 of training and the subse-
quent escape latencies to reach the hidden platform on
days 3–7 of training are illustrated in Fig. 1a. First, the
latency to reach the visible platform was not affected by
genotype (F(1, 60) = 0.179, P = 0.674), Aβ25-35 injection
(F(1, 60) = 0.054, P = 0.818), or the genotype × Aβ25–35
interaction (F(1, 60) = 3.159, P = 0.081). Subsequently,
repeated-measures ANOVA revealed that the escape la-
tency to reach the hidden platform progressively de-
creased with training days in all groups (F(4, 240) =
71.948, P < 0.001), and this effect was influenced by
genotype (F(1, 60) = 190.133, P < 0.001), Aβ25–35 (F(1, 60) =
39.457, P < 0.001), and the genotype × Aβ25–35 inter-
action (F(1, 60) = 36.701, P < 0.001). The seipin-KO mice
required longer times to reach the hidden platform on
days 5–7 of training than did the WT mice (P < 0.01).
Furthermore, the Aβ25–35-injected (1.2 nmol/mouse) sei-
pin-KO mice exhibited a significantly increased escape
latency to the hidden platform (Aβ25–35-KO mice, P <
0.01) compared with the seipin-KO mice, but this effect
was not observed in the Aβ25–35-injected WT mice
(Aβ25–35-mice, P > 0.05) relative to the non-injected WT
mice. However, the mean swimming speeds during the
visible platform and hidden platform tests exhibited by
Aβ25–35-mice (0.26 ± 0.01 m/s, P > 0.05), seipin-KO mice
(0.27 ± 0.03 m/s, P > 0.05), and Aβ25–35-KO mice (0.27 ±
0.04 m/s, P > 0.05) were not significantly different from
those of the WT mice (0.26 ± 0.03 m/s).
A probe test was performed 24 h after the hidden plat-
form test to measure the strength of the memory trace.
The swimming times spent in the target quadrant, op-
posite quadrant, and right and left adjacent quadrants
are showed in Fig. 1b. The main effect of genotype (F(1,
60) = 74.061, P < 0.001) and Aβ25–35 (F(1, 60) = 11.813, P =
0.001) were that the seipin-KO mice spent less swim-
ming time in the target quadrant than the WT mice (P
< 0.01). Furthermore, there was a significant interaction
of genotype × Aβ25–35 (F(1, 60) = 13.716, P < 0.001). Not-
ably, the swimming time in the target quadrant of the
Aβ25–35-KO mice was shorter than that of the seipin-KO
mice (P < 0.01), whereas the Aβ25–35-WT mice exhibited
no significant difference compared with the WT mice
(P > 0.05).
Spatial working memory performance was assessed
with a Y-maze task. There was a main effect of genotype
on the alternation ratio (F(1, 60) = 18.472, P < 0.001;
Fig. 1c), but no effect on the number of arm entries was
observed (F(1, 60) = 0.165, P = 0.686; Fig. 1d). The alterna-
tion ratio of the seipin-KO mice was reduced compared
to that of the WT mice (P < 0.05). Additionally, there
was a significant interaction of genotype × Aβ25–35 for
the alternation ratio (F(1, 60) = 7.214, P = 0.009). Notably,
Aβ25–35-KO mice exhibited a significant reduction in the
alternation ratio compared with the seipin-KO mice (P
< 0.05).
Activation of PPARγ prevents Aβ25–35-induced cognitive
deficits in seipin-KO mice
The level of hippocampal PPARγ exhibited a main effect
of genotype (F(1, 28) = 12.778, P < 0.001; Fig. 2a) but no
effect of Aβ25–35 (F(1, 28) = 0.037, P = 0.848) or geno-
type × Aβ25–35 interaction (F(1, 28) = 0.374, P = 0.546).
Compared with the WT mice, the level of hippocampal
PPARγ was remarkably reduced in the seipin-KO mice
(P < 0.05) but was not significantly different compared
with that in the Aβ25–35-KO mice (P > 0.05).
Consistent with the report by Zhou et al. [7], the
treatment of the seipin-KO mice with the PPARγ agonist
rosiglitazone (rosi, 5 mg/kg, p.o.) for consecutive 17 days
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corrected the prolongation of escape latencies to reach the
hidden platform (P < 0.05, n = 16; Fig. 2c-i) and the de-
crease in the swimming time of target quadrant (P < 0.05,
n = 16; Fig. 2d) and the alternation ratio of Y-maze (KO: P
< 0.05, n = 8; Aβ25–35-KO: P < 0.05, n = 8; Fig. 2e). To test
the involvement of the reduced PPARγ level in the Aβ25–35-
induced cognitive deficits, the rosi treatment was given for
consecutive 17 days starting from 2 days before the Aβ25–35
Fig. 1 Seipin deficiency enhances Aβ25–35-induced cognitive deficits. a The latencies (s) to reach the visible and hidden platforms (upper panel) and the
swimming speeds (m/s, bottom panel) of WT mice (WT), Aβ25–35 mice (Aβ), seipin-KO mice (KO), and Aβ25–35-KO mice (KO/Aβ) in the Morris water maze
(MWM) test. The left panels illustrate representative swimming tracks of the mice searching for the underwater platform on day 5 after training. The black
dots indicate the position of the hidden platform. **P< 0.01 vs. WT mice; ##P< 0.01 vs. seipin-KO mice (repeated-measures ANOVA with Bonferroni’s test).
b The bars represent the percentages of time spent in the target quadrant (TQ), opposite quadrant (OQ), and right (R) and left (L) adjacent quadrants (AQ)
of the probe test. The left panels illustrate typical tracks. **P< 0.01 vs. WT mice; ##P< 0.01 vs. seipin-KO mice (two-way ANOVA with Bonferroni’s test). c, d
The bar graphs display group means in the alternation rate (%) and the numbers of arm entries (8 min) in the Y-maze (Y-M) task. *P< 0.05 and **P< 0.01
vs. WT mice; #P< 0.05 vs. seipin-KO mice (two-way ANOVA with Bonferroni’s test)
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injection (Fig. 2b). In comparison with the vehicle-treated
Aβ25–35-KO mice, the rosi treatment in the Aβ25–35-KO
mice could perfectly reduce their escape latencies reaching
the hidden platform (P < 0.01, n = 16; Fig. 2c-ii) and in-
crease the swimming time in the target quadrant (P < 0.01,
n = 16) and alternation ratio in the Y-maze (P < 0.05, n = 8).
Seipin deficiency enhances Aβ25–35-induced death of
neuronal cells via PPARγ reduction
There was no main effect of genotype (F(1, 28) = 1.572, P =
0.220; Fig. 3a) or Aβ25–35 (F(1, 28) = 2.091, P = 0.159) on the
number of pyramidal cells in the hippocampal CA1
region; however, there was a significant genotype ×Aβ25–35
Fig. 2 Activation of PPARγ prevents enhanced Aβ25–35-induced cognitive deficits by seipin deficiency. a The bars indicate the densitometric values of the
hippocampal PPARγ protein in WT mice (WT), Aβ25–35 mice (Aβ), seipin-KO mice (KO), and Aβ25–35-KO mice (KO/Aβ). *P < 0.05 vs. WT mice (two-way
ANOVA with Bonferroni’s test). b Time chart of the experimental procedure. MWM Morris water maze task, Y-M Y-maze task. c-i and c-ii Each point
represents the group mean latency (s) to reach the visible and hidden platforms in WT mice, vehicle-treated seipin-KO mice (KO), rosi-treated seipin-KO
mice (KO/rosi), Aβ25–35-KO mice (KO/Aβ), and Aβ25–35-KO mice (KO/Aβ/rosi). *P < 0.05 and **P < 0.01 vs. WT mice; #P < 0.05 and ##P < 0.01 vs. seipin-KO
mice; ++P < 0.01 vs. KO/Aβ mice (repeated-measures ANOVA with Bonferroni’s test). d The bars represent the percentages of time spent in a target
quadrant of the probe test. *P < 0.05 and **P < 0.01 vs. WT mice; #P < 0.05 vs. seipin-KO mice; ++P < 0.01 vs. KO/Aβ mice (two-way ANOVA
with Bonferroni’s test). e Bar graph indicates the alternation rates (%) in the Y-maze task. *P < 0.05 vs. WT mice; #P < 0.05 vs. seipin-KO
mice; +P < 0.05 vs. KO/Aβ mice (two-way ANOVA with Bonferroni’s test)
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interaction (F(1, 28) = 4.294, P = 0.048). Stereological
counts of the surviving pyramidal cells revealed an
approximately 35 % loss of pyramidal cells in the
Aβ25–35-KO mice (P < 0.01) and no loss in the Aβ25–35-
mice (P > 0.05). As illustrated in Fig. 3b, large numbers of
Hoechst-positive (Hoechst+) cells were observed in the
Aβ25–35-KO mice (P < 0.01, n = 8) but not in the seipin-KO
mice (P > 0.05, n = 8) or the Aβ25–35-mice (P > 0.05, n = 8).
The rosi treatment in the Aβ25–35-KO mice could attenu-
ate the deaths of pyramidal cells (P < 0.05) and the number
of Hoechst+ cells (P < 0.01), which were sensitive to the
PPARγ antagonist GW9962 (pyramidal cells: P < 0.05;
Fig. 3 Activation of PPARγ attenuates enhanced Aβ neurotoxicity by seipin deficiency. a Representative images of the hippocampal CA1 regions
(5-μm sections stained with toluidine blue) in WT mice (WT), Aβ25–35 mice (Aβ), seipin-KO mice (KO), Aβ25–35-KO mice (KO/Aβ), rosi-treated Aβ25–35-KO mice
(KO/Aβ/rosi), GW9662-treated seipin-KO mice (KO/GW), and KO/Aβ/rosi mice (KO/Aβ/rosi/GW). PcL pyramidal cell layer, OL oriens layer. Scale bars= 50 μm.
The bar graph represents the stereological counts of the surviving pyramidal cells. **P< 0.01 vs. WT mice; #P< 0.05 vs. Aβ25–35-KO mice;
+P< 0.05 vs. KO/
Aβ/rosi mice (three-way ANOVA with Bonferroni’s test). b Representative images of Hoechst staining in the hippocampal CA1 regions. The white arrows
indicate the Hoechst+ cells. PcL: pyramidal cell layer; RL: radiatum layer. Scale bars = 50 μm. The bars indicate the density of Hoechst+ cells. **P< 0.01 vs.
WT mice; ##P< 0.01 vs. Aβ25–35-KO mice; ++P< 0.01 vs. KO/Aβ/rosi mice (three-way ANOVA with Bonferroni’s test)
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Hoechst+ cells: P < 0.01). The administration of GW9962
alone in the seipin-KO mice did not affect the survival of
pyramidal cells (P > 0.05). Similarly, the Aβ1–42 injection in
the seipin-KO mice rather than the WT mice caused ap-
proximately 30 % death of pyramidal cells (P < 0.05, n = 8;
Additional file 1: Figure S1), which was prevented by the
rosi treatment (P < 0.05, n = 8).
Seipin deficiency facilitates Aβ25–35-induced inflammation
via PPARγ reduction
Sequentially, we observed that GFAP+ astrocytes
expressed highly the seipin protein in the hippocampal
CA1 region (upper panels in Fig. 4a) but Iba1+ microglia
did not (bottom panels). The numbers of Iba1+ cells
(P > 0.05, n = 8; Fig. 4b) or GFAP+ cells (P > 0.05, n = 8;
Fig. 4c) in the seipin-KO mice did not differ from those
in the WT mice. Morphological analysis revealed GFAP+
stellated-shaped astrocytes with thin processes that
denoted a resting phenotype or with thick processes that
reflected an activated phenotype [40]. Notably, the num-
bers of Iba1+ cells (P < 0.01, n = 8) and GFAP+ activated
astrocytes (P < 0.01, n = 8) were significantly increased in
the Aβ25–35-KO mice compared with the seipin-KO
mice, which were reduced by the rosi treatment (Iba1+:
P < 0.01, n = 8; GFAP+: P < 0.05, n = 8). The inhibitory
effects of rosi on the activation of Iba1+ cells (P < 0.01, n
= 8) and GFAP+ activated astrocytes (P < 0.05, n = 8) in
the Aβ25–35-KO mice could be blocked by the PPARγ
antagonist GW9962. By contrast, Aβ25–35 mice did not
show the changes in the numbers of Iba1+ cells (P >
0.05, n = 8) and GFAP+ cells (P > 0.05, n = 8) compared
to the WT mice. Additionally, the Aβ1–42 injection could
increase the numbers of Iba1+ cells (P < 0.01, n = 8;
Additional file 1: Figure S2) and GFAP+ activated astro-
cytes (P < 0.01, n = 8) in the seipin-KO mice but not in
the WT mice, which was sensitive to the rosi treatment
(Iba1+ cells: P < 0.01, n = 8; GFAP+ cells: P < 0.05, n = 8).
Further experiment was designed to examine the influ-
ence of seipin deficiency on Aβ-induced inflammatory
reactions using Western blot. Notably, there were a
main effect of genotype for the levels of hippocampal
TNF-α (F(1, 28) = 29.253, P < 0.001; Fig. 4d) and IL-6 (F(1,
28) = 65.073, P < 0.001; Fig. 4e). Additionally, there was a
significant genotype × Aβ25–35 interaction, because the
levels of TNF-α (P < 0.01) and IL-6 (P < 0.01) were
higher in the Aβ25–35-KO mice than those in the seipin-
KO mice. However, the levels of TNF-α (P > 0.05) and
IL-6 (P > 0.05) exhibited no differences between the WT
mice and Aβ25–35 mice. Furthermore, the increased
TNF-α and IL-6 levels in the seipin-KO mice (TNF-α: P
< 0.05; IL-6: P < 0.01) and the Aβ25–35-KO mice (TNF-α:
P < 0.01; IL-6: P < 0.01) were attenuated by the rosi
treatment.
Seipin deficiency increases GSK3β activity via PPARγ
reduction
GSK3β has been reported to modulate pro-inflammatory
cytokines [26]. GSK3β activity is negatively and posi-
tively regulated by phosphorylation at Ser9 and Tyr216,
respectively. To explore the mechanisms underlying the
seipin deficiency-increased TNF-α and IL-6, we exam-
ined the levels of hippocampal GSK3β phosphorylation
(phospho-GSK3β) at Tyr216 and Ser9 [41]. Compared
with the WT mice, the level of Tyr216 phospho-GSK3β
was elevated (P < 0.01, n = 8; Fig. 5a) and the level of
Ser9 phospho-GSK3β was reduced in the seipin-KO
mice (P < 0.01, n = 8; Fig. 5b); and these levels were not
affected by the Aβ25–35 injection. Interestingly, the rosi
treatment in the seipin-KO mice obviously corrected the
elevation of Tyr216 phospho-GSK3β (P < 0.01, n = 8)
and the reduction of Ser9 phospho-GSK3β (P < 0.01, n =
8). Additionally, the rosi treatment of the WT mice
increased Ser9 phospho-GSK3β (P < 0.01, n = 8) but had
no effect on Tyr216 phospho-GSK3β (P > 0.05, n = 8).
The activation of GSK3β is required to activate tyro-
sine phosphorylation of STAT3 in astrocytes and micro-
glia [24]. Similarly, the level of hippocampal STAT
phosphorylation (phospho-STAT) in the seipin-KO mice
was elevated compared with that in the WT mice (P <
0.01, n = 8; Fig. 5c). The level of phospho-STAT3 in the
seipin-KO mice was further increased by the rosi treat-
ment (P < 0.01, n = 8) but was not affected by the Aβ25–
35 injection (P > 0.05, n = 8). Additionally, the rosi treat-
ment increased the level of phospho-STAT3 in the WT
mice (P < 0.05, n = 8).
Discussion
The present study provides, for the first time, in vivo
evidence that the seipin deficiency in astrocytes can
facilitate the Aβ25–35/1–42-induced neuroinflammation to
aggravate the Aβ25–35/1–42 neurotoxicity. This conclusion
was deduced mainly from the following observations: (1)
seipin was highly expressed in hippocampal pyramidal
cells and astrocytes; (2) the seipin deficiency did not
alter the number of neuronal cells, astrocytes, and
microglia, but the levels of IL-6/TNF-α were higher in
the seipin-KO mice than those in WT mice; (3) the
injection (i.c.v.) of Aβ25–35 (1.2 nmol/mouse) or Aβ1–42
(0.1 nmol/mouse) could stimulate the activation of as-
trocytes and microglia and further increased the expres-
sion of IL-6/TNF-α in seipin-KO mice, but not in the
WT mice; (4) the injection (i.c.v.) of Aβ25–35 or Aβ1–42,
at the non-neurotoxic doses in WT mice, caused approxi-
mately 30–35 % death of pyramidal cells with a significant
increase of apoptotic cells in hippocampal CA1 of the
seipin-KO mice leading to the impairment of spatial
memory.
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Fig. 4 Activation of PPARγ reduces the enhanced Aβ-induced inflammation by seipin deficiency. a The upper panel shows representative fluorescence
images by seipin (red color, left column) and GFAP (green color, middle column) double immuno-staining in hippocampal CA1 regions of WT mice
(scale bar = 50 μm). The white arrows indicate seipin/GFAP-positive cells (yellow color, right column). The bottom panels shows the representative
pictures of seipin (green color, left column) and Iba1 (red color, middle column) double immuno-staining in hippocampal CA1 regions of WT mice
(scale bar= 50 μm). PcL pyramidal cell layer, RL radiatum layer. b, c Representative pictures of Iba1+ cells (scale bar = 50 μm) and GFAP+ cells (scale bar =
25 μm) in the hippocampal CA1 regions of WT mice (WT), Aβ25–35 mice (Aβ), seipin-KO mice (KO), Aβ25–35-KO mice (KO/Aβ), and rosi-treated KO/Aβ
mice (KO/Aβ/rosi). The bar graphs represent the densities of Iba1+ microglial and GFAP+-activated astrocytes normalized by the control value obtained
from WT mice. **P < 0.01 vs. seipin-KO mice; #P < 0.05 and ##P < 0.01 vs. Aβ25–35-KO mice; +P < 0.05 and ++P < 0.01 vs. KO/Aβ/rosi mice
(three-way ANOVA with Bonferroni’s test). d, e Levels of hippocampal TNF-α and IL-1β. *P < 0.05 and **P < 0.01 vs. WT mice; #P < 0.05 and
##P < 0.01 vs. seipin-KO mice; ++P < 0.01 vs. Aβ25–35-KO mice (three-way ANOVA with Bonferroni’s test)
Qian et al. Journal of Neuroinflammation  (2016) 13:145 Page 10 of 14
Seipin deficiency in astrocytes facilitates
Aβ-neuroinflammation via the reduction of PPARγ
The treatment of astrocytes and microglia with Aβ1–42
can increase the production of IL-6 and TNF-α, which is
inhibited by the activation of PPARγ [42]. The PPARγ
agonists can prevent the overproduction of IL-6 and
TNF-α in astrocytes and microglia treated with lipopoly-
saccharide (LPS) [43]. The injection (i.c.v.) of Aβ25–35
stimulates microglial activation in the brains of C57BL/
6J mice [44]. The injection (i.c.v.) of Aβ25–35 (1.2 nmol/
Fig. 5 Activation of PPARγ depresses enhanced GSK3β activity by seipin deficiency. a–c Levels of hippocampal Tyr216 phospho-GSK3β, Ser9
phospho-GSK3β, and phospho-STAT3 in WT mice (WT), Aβ25–35 mice (Aβ), seipin-KO mice (KO), Aβ25–35-KO mice (KO/Aβ), and rosi-treated Aβ mice and
KO/Aβ mice. Levels of Tyr216 phospho-GSK3β and Ser9 phospho-GSK3β were first normalized to the amount of GSK3β protein and subsequently
normalized to the basal values in WT mice. **P < 0.01 vs. WT mice; ##P < 0.01 vs. Aβ25–35-KO mice (three-way ANOVA). The levels of phospho-STAT3
were normalized to the amount of STAT3 protein and subsequently normalized to the basal values in WT mice. **P < 0.01 vs. WT mice; #P < 0.05 vs.
Aβ25–35-KO mice (three-way ANOVA with Bonferroni’s test)
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mouse) or Aβ1–42 (0.1 nmol/mouse) was insufficient to
stimulate the activation of astrocytes and microglia or to
increase the production of TNF-α or IL-6 in WT mice.
However, this injection (i.c.v.) of Aβ25–35 or Aβ1–42 in the
seipin-KO mice caused the activation of astrocytes and
microglia with an obvious increase in the level of TNF-α or
IL-6. Interestingly, in particular, the activation of PPARγ in
the seipin-KO mice was able to prevent the Aβ25–35/1–42-in-
duced neuroinflammation. Similarly, PPARγ-deficient het-
erozygous mice develop an exacerbated experimental
allergic encephalomyelitis (EAE) in comparison with the
wild-type littermates [15]. The exacerbation of EAE by the
PPARγ antagonists associates with an augmented neural in-
flammation [16]. Astrocytes and microglia are fundamental
cellular targets for the beneficial effects of PPARγ ligands
[13]. We observed the seipin expression in hippocampal
astrocytes. Although the number of astrocytes in the hippo-
campal CA1 region of the seipin-KO mice did not differ in
comparison with the WT mice, the levels of hippocampal
TNF-α and IL-6 in the seipin-KO mice were higher than
those in the WT mice. In particular, the elevation of TNF-α
or IL-6 in the seipin-KO mice was reduced by the PPARγ
agonist. Thus, it may be possible that the reduction of
PPARγ leads to the overproduction of pro-inflammatory
cytokines in the seipin-KO mice, which facilitates the Aβ25–
35/1–42-induced neuroinflammation. Another indirect but
important supporting data is that the increased TNF-α and
IL-6 in the seipin-KO mice could be corrected by the
activation of PPARγ. Therefore, the findings give an indica-
tion that the seipin deficiency in astrocytes is able to facili-
tate the Aβ-induced neuroinflammation probably through
reducing PPARγ to elevate the levels of TNF-α and IL-6.
Seipin deficiency enhances GSK3β activity to increase
pro-inflammatory cytokines
GSK3β has been identified as a strong promoter of pro-
inflammatory cytokines, including IL-6 and TNF-α [25, 26].
The inhibition of GSK3β increases inflammatory tolerance
and reduces inflammatory sensitization in the brain [45].
GSK3β inhibition in glial cells reduces pro-inflammatory
responses by blocking STAT3 signaling [46]. The inhibition
of GSK3 reduces STAT3 activation, IL-6 production, and
GFAP up-regulation by LPS-stimulated primary glia [47].
The activation of PPARγ potentially suppresses the activa-
tor of STAT [48]. The level of STAT3 phosphorylation was
significantly increased in the seipin-KO mice [10]. STAT3
activation is highly dependent on GSK3β in mouse primary
astrocytes [24]. Notably, the catalytic activity of GSK3β in
seipin-KO mice was enhanced as indicated by the elevation
of Tyr216 phospho-GSK3β and the reduction of Ser9
phospho-GSK3β. The activation of PPARγ regulates nega-
tively the expressions of GSK3β [49], but the level of
GSK3β protein failed to be increased in the seipin-KO
mice. Strangely enough, the administration of rosi to the
seipin-KO mice could suppress the increase of GSK3β
activity but further enhanced the phosphorylation of
STAT3. Therefore, it is indicated that seipin deficiency in
astrocytes through reducing PPARγ enhances the GSK3β
activity rather than the STAT3 signaling to increase the
production of TNF-α and IL-6. On the other hand, GSK3β
regulates interferon-γ (IFN-γ) signaling and is involved in
IFN-γ-induced inflammation [50]. Thus, further studies are
required to examine whether the GSK3β activity in seipin-
KO mice through synergistically facilitating IFN-γ-induced
STAT1 activation increases the production of TNF-α [41].
Seipin deficiency enhances Aβ-neurotoxicity via the
reduction of PPARγ
A principal finding in this study is that seipin deficiency in
hippocampal neuronal cells enhances the Aβ25–35/1–42
neurotoxicity as indicated by a massive death of pyramidal
cells in the seipin-KO mice treated with the Aβ25–35
(1.2 nmol/mouse) or Aβ1–42 (0.1 nmol/mouse), generally
non-neurotoxic doses in the WT mice or control mice
[29]. The level of the hippocampal PPARγ was signifi-
cantly reduced in the seipin-KO mice. The decline of
PPARγ in the seipin-KO mice [11] or the neuronal specific
PPARγ knockout in mice [51] did not cause the loss of
neuronal cells in the hippocampus. The rosi treatment
could significantly reduce the Aβ25–35/1–42-induced death
of pyramidal cells in the seipin-KO mice. Activated micro-
glia and reactive astrocytes can produce cytokines, reactive
oxygen species, and other neurotoxic substances to cause
neuronal apoptosis and other series of pathologic events.
The progressive neuroinflammation and neuronal apop-
tosis in AD is considered to be a consequence of the Aβ-
neurotoxic properties [52, 53]. Our data support the
notion that Aβ25–35/1–42-induced neuroinflammation in
the seipin-KO mice causes the death of neuronal cells.
Zhao et al. [51] reported that neuronal PPARγ deficiency
increased susceptibility to brain damage after cerebral
ischemia through suppressing the expressions of Cu-Zn
superoxide dismutase (SOD1), catalase (CAT), and gluta-
thione S-transferase (GST). However, the levels of hippo-
campal SOD1, CAT, and GST expression in seipin-KO
mice did not differ from WT mice (data not shown). Add-
itionally, Ito et al. reported that mutations (N88S/S90L) of
the seipin gene can cause the formation of cytoplasmic
inclusions and enhance ubiquitination, which leads to
endoplasmic reticulum (ER) stress [54]. However, this idea
is not supported because the levels of the ER stress makers
BiP and CHOP in seipin-KO mice are not increased [11].
Conclusions
Using the seipin-KO mice with reduction of PPARγ, we
observed that seipin deficiency elevated the activity of
GSK3β to enhance the production of TNF-α and IL-6,
which in turn triggered and strengthened the Aβ25–35-
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induced inflammatory responses leading to the death of
neuronal cells and the spatial cognitive deficits. This is
particularly true of neuroinflammation, which contributes
to a broad range of neurodegenerative diseases [55].
Although much more work needs to be performed in the
future, this is the first report to demonstrate that the
expression of seipin in hippocampal astrocytes is required
for regulating the inflammatory responses and preventing
the neurodegeneration.
Highlights
(1)Hippocampal GSK3β activity and IL-6/TNF-α were
slightly increased in seipin-KO mice.
(2)PPARγ agonist inhibits increased GSK3β activity and
IL-6/TNF-α in KO mice.
(3)Low-dose Aβ25–35 causes death of pyramidal cells in
KO mice, not in WT mice.
(4)Aβ25–35 activates microglia and astrocytes to
increases IL-6/TNF-α in KO mice.
(5)PPARγ agonist prevents Aβ25–35-neuroinflammation
and -neurotoxicity in KO mice.
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Additional file 1: Effects of neuronal seipin knockout on Aβ1-42-induced
neurotoxicity and neuroinflammation. (116 KB)
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